The extensive DNA test of Hartwig Medical Foundation visualizes all characteristics of the tumor DNA, whereby a (more) complete image of possibilities for patient treatment arises. This way the chance the patient receives the right treatment increases, or the DNA test shows that a certain type of drug possibly does not work at all or less properly. Besides the customized treatment which are given in the ‘standard of care’ today, the extensive DNA test also brings out all possible options for participation in current experimental clinical studies.
The extensive DNA test
This DNA test is suitable for all adult patients with metastasised cancer (except leukaemia) provided that a sample of the tumor can be taken safely.
Present day cancer care for patients already encompasses several (molecular) diagnostic tests, including DNA tests. These tests usually focus on a (more limited) number of DNA characteristics of the tumor and only for a limited number of cancer.
Patients who no longer have a treatment option and patients suffering from a rare type of cancer for which no standardised treatments are available, benefit most from this extensive DNA test.
Consultation with the treating specialist is always required in order to establish whether the extensive DNA test can be beneficial for a patient.
The extensive DNA test is already used for two clinical studies in The Netherlands; more precisely the CPCT-02-study and the WIDE-study. This last study is carried out in cooperation with the Antoni van Leeuwenhoek Hospital (Dutch). With the study requirements at hand the treating specialist will be able to determine whether it is possible or useful for the patient, who is already treated in one of the participating hospitals, to participate in the clinical study in question.
Patients who no longer have a treatment option and patients suffering from a rare type of cancer for which no standardised treatments are available, but who do not meet the requirements of the studies mentioned above, might still be eligible for the extensive DNA test. For example in a second opinion procedure.
In consultation with the treating specialist, a referral to the Erasmus MC (Rotterdam) for a second opinion can be requested. The second opinion procedure evaluates the benefit of an extensive DNA test for the selection of treatment options in a clinical study setting. This will be discussed with the patient.
Erasmus MC also has a Cancer Instite. More general information can be read on their website.
Tumor tissue taken in routine procedures in hospitals is quite often not suitable for the extensive DNA test of Hartwig Medical Foundation. Immediately after the tumor tissue is taken it has to be stored in a specific manner (freshly frozen).
In The Netherlands 44 hospitals are familiar with this storage procedure. Hartwig Medical Foundation can answer any questions about the required procedures of the extensive DNA test.
If you as a patient or a doctor have any general questions about the extensive DNA test or its application or you wish to have more information about the options to participate in one of the above studies please contact Hartwig Medical Foundation. Preferably send your questions by e-mail, but you may also call us on 020 – 235 2640.
Hartwig Medical Foundation has carried out the extensive DNA test in its laboratory since the end of 2017, for which we have an ISO17025 accreditation. Click here for the scope of this accreditation. The performance of data analysis and data storage is in accordance with NEN7510 (Dutch). The extensive DNA test is validated and has by now been carried out for more than 4,000 patients in various Dutch studies.